Cadherin 17 Target Analysis Report 2022: Opportunity for Drug Discovery and Development as the Landscape is Very Favorable for New Entrants Evan as the 1st Molecules have Entered Clinical Development

December 16, 2022

Dublin, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The "Cadherin 17: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to's offering. CDH17 provides a great opportunity for drug discovery and development as the competitive landscape still is very favorable for new entrants, but the first molecules have entered clinical development.Cadherins are a family of glycoproteins responsible for calcium ion-dependent cell adhesion. There are more than 100 types of cadherins in humans, and many of them are not only responsible for cell adhesion but also involved in tumorigenesis. Cadherin 17 (CDH17), also known as human liver intestine-cadherin (LI-cadherin), or intestinal human peptide transporter-1 (HPT-1), is a non-classical cadherin composed of an ectodomain consisting of seven extracellular cadherin (EC) repeats, a single transmembrane domain, and a short cytoplasmic domain.CDH17 is a highly specific marker of gastrointestinal epithelium; most gastrointestinal adenocarcinomas are CDH17-positive with strong membranous staining. However, healthy tissue colonic mucosa and duodenal mucosa also are positive for CDH17 which prevented consideration of CDH17 as an ideal tumor associated antigen for development of CDH17-targeted therapies.It was only very recently, that investigators discovered that CDH17 is masked in healthy tissue and is not attacked by large molecules or cells. Thus, CDH17 represents a class of previously unappreciated tumor-associated antigens that is 'masked' in healthy tissues from attack by CAR T cells for developing safer cancer immunotherapy. Effector-enhanced antibodies and cells such as antibody-drug conjugates, chimeric antigen receptor (CAR) T-cells, and bispecific antibodies redirecting T-cells or specifically activating T-cells will be enabled by and benefit from the cancer "selective" expression profile to avoid on-target, off-tumor toxicity.This report describes and analyzes: The scientific rationale for CDH17-targeted therapies based on target characteristics and its differential expression profilePreclinical proof-of-concept of CDH17-targeted different drug modalitiesClinical indications suitable for development of CDH17-targeted therapies and their patient populationsThe competitive landscape of CDH17-targeted drug modalities in developmentSpecific profiles of CDH17-targeted drug modalitiesProfiles of companies active in the development of anti-CDH17 therapy candidates Key Topics Covered: 1 Target Background2 Target Antigen Expression Profile3 Preclinical Proof-of-Concept4 Clinical Indications & Patient Populations5 Competitive Landscape & Drug Modalities6 Drug & Cell Therapy Candidate Profiles6.1 CAR T-Cells6.2 Pro-Apoptotic Bispecific Antibodies6.3 T-Cell Redirecting Bispecific Antibodies6.4 Naked Antibodies7 Company Profiles8 References For more information about this report visit

© 2024